Quick Answer
BIODESIX INC reported R&D Expense of $12.00 million for fiscal year 2025.
BIODESIX INC R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $12.00M | +25.5% |
| 2024 | $9.56M | -4.3% |
| 2023 | $9.99M | -23.8% |
| 2022 | $13.10M | +2.4% |
| 2021 | $12.79M | +18.2% |
| 2020 | $10.82M | +3.3% |
| 2019 | $10.47M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $2.99M | +17.5% | -8.5% |
| June 30, 2025 | $3.27M | +27.8% | +13.9% |
| March 31, 2025 | $2.87M | +40.7% | +12.7% |
| September 30, 2024 | $2.55M | +31.4% | -0.4% |
| June 30, 2024 | $2.56M | -12.1% | +25.4% |
| March 31, 2024 | $2.04M | -37.3% | +5.3% |
| September 30, 2023 | $1.94M | -34.7% | -33.4% |
| June 30, 2023 | $2.91M | -13.4% | -10.5% |
- BIODESIX INC showed an increase of +25.5% in R&D Expense compared to the prior fiscal year.
- Over the 2019–2025 period, BIODESIX INC’s r&d expense has grown by 14.6% (from $10.47 million to $12.00 million).
- The most recent figure is from BIODESIX INC’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: